Crinetics Pharmaceuticals
CRNX
50 hedge funds and large institutions have $503M invested in Crinetics Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 17 increasing their positions, 11 reducing their positions, and 9 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
55% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 11
11% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 9
9% more capital invested
Capital invested by funds: $463M → $503M (+$40.3M)
2.53% more ownership
Funds ownership: 67.3% → 69.83% (+2.5%)
2% more funds holding
Funds holding: 49 → 50 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$7.71M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$6.21M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$4.9M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$2.53M |
| 5 |
EU
Emory University
Atlanta,
Georgia
|
+$2.42M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Laurion Capital Management
New York
|
-$3.37M |
| 2 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
-$1.42M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$1.31M |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
-$1.15M |
| 5 |
MWNA
Marshall Wace North America
New York
|
-$895K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
LCM
51
Laurion Capital Management
New York
| – | -$3.37M | -117,700 | Closed |
|
|
FCMI
52
Foresite Capital Management IV
Larkspur,
California
| – | -$1.42M | -49,600 | Closed |
|
|
MWNA
53
Marshall Wace North America
New York
| – | -$895K | -31,241 | Closed |
|
|
DIM
54
DC Investments Management
Mclean,
Virginia
| – | -$701K | -24,480 | Closed |
|
|
BCM
55
BlueCrest Capital Management
St Helier,
Jersey
| – | -$381K | -13,289 | Closed |
|
|
LCM
56
Landscape Capital Management
Englewood,
New Jersey
| – | -$341K | -11,893 | Closed |
|
|
ZP
57
Zimmer Partners
New York
| – | -$287K | -10,000 | Closed |
|
58
Barclays
London,
United Kingdom
| – | -$75K | -2,608 | Closed |
|
|
FIA
59
FNY Investment Advisers
New York
| – | -$57K | -2,000 | Closed |
|
CRNX Hedge Fund Activity: Q4 2018 in Review
50 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Crinetics Pharmaceuticals (CRNX) for Q4 2018, worth a combined $503M — up 8.7% from $463M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new CRNX positions and 9 closed out — a net gain of 1 holder — while 17 added to existing stakes and 11 trimmed.
The largest buyer was BlackRock, adding an estimated $7.71M. The largest seller was Laurion Capital Management, exiting entirely with an estimated $3.37M sold.
- 50 institutional investors held Crinetics Pharmaceuticals (CRNX) as of Q4 2018, up from 49 in Q3 2018.
- Funds reported $503M of Crinetics Pharmaceuticals stock for Q4 2018, up 8.7% quarter-over-quarter.
- 10 funds opened new Crinetics Pharmaceuticals positions in Q4 2018 and 9 closed out, a net change of +1 holder.
- The largest Crinetics Pharmaceuticals buyer in Q4 2018 was BlackRock, an estimated $7.71M added.
- The largest Crinetics Pharmaceuticals seller in Q4 2018 was Laurion Capital Management, an estimated $3.37M sold.
Based on aggregated 13F filings for Q4 2018.